Skip to main content
OpenTrials

Clinical trial condition

Metastatic Renal Cell Carcinoma

Explore clinical trials studying Metastatic Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

125 public trials 25 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Renal Cell Carcinoma trial results

Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

NCT01550367

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Loyola University Chicago Maywood, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dartmouth-Hitchcock Medical Center Hanover, New Hampshire, United States
View Trial Details
Completed

Testosterone in Metastatic Renal Cell Carcinoma Patients

NCT03379012

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • A.I. Kryzhanovsky Krasnoyarsk Cancer Center Krasnoyarsk, Russia
  • Kidney Cancer Research Bureau Moscow, Russia
  • RUDN University Moscow, Russia
  • City Clinical Oncology Center Saint Petersburg, Russia
View Trial Details
Completed

A Study for Participants With Metastatic Renal Cell Carcinoma

NCT00709995

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vienna, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Villejuif, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Rome, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Warsaw, Poland
View Trial Details
Completed

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

NCT03519542

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, A Coruña, Spain
  • Hospital Marqués de Valdecilla Santander, Cantabria, Spain
  • Hospital Universitario central de Asturias Oviedo, Principality of Asturias, Spain
  • Hospital Universitarios de Burgos Burgos, Spain
View Trial Details
Completed

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

NCT01415167

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +24 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Moores UCSD Cancer Center La Jolla, California, United States
  • USC Norris Cancer Center Los Angeles, California, United States
  • Southern California Permanente Medical Group Riverside, California, United States
View all 45 locations
View Trial Details
Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

NCT01136733

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Tucson, Arizona, United States
  • Orange, California, United States
  • San Diego, California, United States
  • Tampa, Florida, United States
View all 37 locations
View Trial Details
Completed

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

NCT03091465

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Hospital General Universitario de Elche Elche, Alicante, Spain
  • Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
  • Corporació Sanitària Parc Taulí Sabadell, Barcelona, Spain
  • Hospital Universitario Mútua Terrassa Terrassa, Barcelona, Spain
View all 57 locations
View Trial Details
Completed

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

NCT02282579

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Hospital Son Espases Palma de Mallorca, Mallorca, Spain
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Vall d' Hebron Barcelona, Spain
  • Hospital San Pedro de Alcántara Cáceres, Spain
View all 34 locations
View Trial Details

Related conditions